在林业发展局批准进行新的ALS治疗研究后,Coya治疗药品库存激增。 Coya Therapeutics' stock surged after FDA clearance for a new ALS treatment study.

在林业发展局接受IND申请COYA 302之后,Coya治疗药物的库存增加,这是对ALS的一种可能的治疗。 Coya Therapeutics' stock rose after the FDA accepted its IND application for COYA 302, a potential treatment for ALS. 这项批准使公司能够开始第二阶段临床研究,从而促使合作伙伴Reddy博士实验室支付420万美元的里程碑式付款。 This approval allows the company to start a Phase 2 clinical study, triggering a $4.2 million milestone payment from partner Dr. Reddy's Laboratories. 尽管最近出现净亏损, Coya还是从分析家那里得到“买入”评级,其目标价格表明有显著的利得。 Despite a recent net loss, Coya received a "buy" rating from analysts with a target price suggesting a significant upside.